Health Source (600380): Performance is in line with expectations, and Tubuu is expected to accelerate its volume quarterly
Health Source (600380): 1Q24 results are in line with expectations, TG-1000 reached the main phase III clinical endpoint
Health Source (600380) Company Information Update Report: Inhalation Formulation Leader's Innovative Drugs and High-Barrier Formulations Accelerate
Open Source Securities released a research report on April 8 stating that it gave Health Yuan (600380.SH) a purchase rating. The main reasons for the rating include: 1) inhaled formulations continue to rise, and revenue from the health products business h
Health Source (600380): Performance is in line with expectations; sales of inhaled formulations slightly exceeded expectations
Health Source (600380) 2023 performance review: rapid growth in inhaled formulations, expected tobramycin doses
Health Yuan (600380) Company's First Coverage Report: Inhalation Formulation Leader Starts a New Journey with Diversified Businesses
Health Yuan (600380): Zuosha collection is under pressure, and Tubu is expected to release volume quickly
Health Yuan (600380): Inhalation formulations maintained a good growth trend in the 1-3 quarter, and the sales expenses rate declined year-on-year
Health Yuan (600380): Macro industry adjustments affect academic promotion and admission performance are basically in line with expectations
Research Report Nuggets 丨 Cinda Securities: Health Yuan released respiratory preparations rapidly in the first half of the year, and R&D varieties ushered in a harvest period for listing
Health Yuan (600380): Respiratory preparations have entered the harvest period, meropenem collection has put pressure on short-term performance
Health Yuan (600380): Steady growth in the first half of the year and impressive revenue performance in the respiratory sector
Health Yuan (600380): Performance is in line with expectations BD further increased
Health Yuan (600380) 2023 semi-annual report review: Outstanding performance in the respiratory field, new products offset the impact of collection
Health Yuan (600380): Respiratory Medicine is growing at an impressive rate and special research and development continues to advance
Health Yuan (600380) Quarterly Report Review: Q1 Performance Meets Expectations, Respiratory Medicine Maintains Rapid Growth Trend
Health Yuan (600380): The annual results are in line with expectations, and the respiratory sector has grown brilliantly
Health Yuan (600380): Steady annual performance growth meets expectations, and respiratory department's performance is impressive
Health Yuan (600380): Performance is in line with expectations, significant release of inhaled formulations
No Data